FOLD Amicus Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FOLD

Price (delayed)

$11.02

Market cap

$3.23B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.59

Enterprise value

$3.42B

Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics ...

Highlights
The EPS has grown by 36% YoY and by 8% from the previous quarter
The net income rose by 34% YoY and by 6% QoQ
Amicus Therapeutics's quick ratio has decreased by 15% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.amicusrx.com
Peers: PLX BIIB BMRN ESPR

Key stats

What are the main financial stats of FOLD
Market
Shares outstanding
293.25M
Market cap
$3.23B
Enterprise value
$3.42B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
23.75
Price to sales (P/S)
8.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.19
Earnings
Revenue
$372.37M
EBIT
-$140.1M
EBITDA
-$133.1M
Free cash flow
-$158.3M
Per share
EPS
-$0.59
Free cash flow per share
-$0.54
Book value per share
$0.46
Revenue per share
$1.26
TBVPS
$1.84
Balance sheet
Total assets
$764.08M
Total liabilities
$630.85M
Debt
$454.29M
Equity
$133.24M
Working capital
$293.8M
Liquidity
Debt to equity
3.41
Current ratio
2.73
Quick ratio
2.09
Net debt/EBITDA
-1.43
Margins
EBITDA margin
-35.7%
Gross margin
90.5%
Net margin
-46.6%
Operating margin
-30%
Efficiency
Return on assets
-23.8%
Return on equity
-147.6%
Return on invested capital
-22.8%
Return on capital employed
-23.6%
Return on sales
-37.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FOLD stock price

How has the Amicus Therapeutics stock price performed over time
Intraday
-0.81%
1 week
2.42%
1 month
-2.56%
1 year
-10.04%
YTD
-9.75%
QTD
-9.38%

Financial performance

How have Amicus Therapeutics's revenue and profit performed over time
Revenue
$372.37M
Gross profit
$336.98M
Operating income
-$111.68M
Net income
-$173.61M
Gross margin
90.5%
Net margin
-46.6%
The operating margin has soared by 60% YoY and by 19% QoQ
Amicus Therapeutics's operating income has surged by 54% YoY and by 14% QoQ
FOLD's net margin is up by 43% year-on-year and by 12% since the previous quarter
The net income rose by 34% YoY and by 6% QoQ

Growth

What is Amicus Therapeutics's growth rate over time

Valuation

What is Amicus Therapeutics stock price valuation
P/E
N/A
P/B
23.75
P/S
8.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.19
The EPS has grown by 36% YoY and by 8% from the previous quarter
The P/B is 68% above the 5-year quarterly average of 14.1 but 19% below the last 4 quarters average of 29.2
The equity has grown by 19% from the previous quarter
FOLD's price to sales (P/S) is 34% lower than its 5-year quarterly average of 13.3 and 13% lower than its last 4 quarters average of 10.1
FOLD's revenue is up by 15% year-on-year and by 6% since the previous quarter

Efficiency

How efficient is Amicus Therapeutics business performance
The ROS has grown by 44% YoY and by 11% from the previous quarter
The ROIC has grown by 30% YoY and by 5% from the previous quarter
FOLD's ROA is up by 26% YoY and by 6% from the previous quarter
Amicus Therapeutics's return on equity has decreased by 19% YoY but it has increased by 6% QoQ

Dividends

What is FOLD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FOLD.

Financial health

How did Amicus Therapeutics financials performed over time
FOLD's total assets is 21% greater than its total liabilities
Amicus Therapeutics's quick ratio has decreased by 15% YoY
FOLD's total assets is up by 4.7% since the previous quarter
The equity has grown by 19% from the previous quarter
FOLD's debt to equity is down by 16% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.